Autolus - About the company
Autolus is a public company based in London (United Kingdom), founded in 2015 by Martin Pule. It operates as a Clinical-stage biopharmaceutical provider developing CAR T therapies for cancer and autoimmune diseases. Autolus has raised $181M in funding from Syncona. The company has 3576 active competitors, including 1211 funded and 831 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Clinical-stage biopharmaceutical provider developing CAR T therapies for cancer and autoimmune diseases. It leverages advanced immune cell engineering, chimeric antigen receptor (CAR) technology, and proprietary T cell programming platforms to create precise, controlled, and highly active therapeutic products designed to improve patient outcomes. Its technology platform combines innovative cell programming capabilities with proprietary viral vector systems and semi-automated manufacturing processes to engineer patient-derived T cells capable of recognizing and eliminating disease-causing cells.
- Website
- www.autolus.com
- Email ID
- *****@autolus.com
- Phone Number
- +44 **********
- Registered Address
- Rockville, Maryland
Key Metrics
Founded Year
2015
Location
London, United Kingdom
Stage
Public
Total Funding
$181M in 5 rounds
Latest Funding Round
Ranked
59th among 3576 active competitors
Annual Revenue
$1M - $10M as on Sep 30, 2016
Employee Count
732 as on Jul 31, 2026
Similar Companies
Exit Details
Public
Legal entities associated with Autolus
Autolus is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
AUTOLUS, INC. CIN: 823234838 , United States, Active | Dec 26, 999 | - | 143 (As on Dec 31, 2024) | - |
Autolus Limited CIN: 09115837 , United Kingdom, Active | Jul 02, 2014 | $1M - $10M (As on Sep 30, 2016) | 302 (As on Sep 30, 2020) |
Autolus's IPO details
Autolus got listed on Jun 22, 2018.
Click here to take a look at Autolus's IPO in detail
Sign up to download Autolus' company profile
Autolus's funding and investors
Autolus has raised a total funding of $181M over 5 rounds. Its first funding round was on Jan 22, 2015. Its latest funding round was a Post IPO round on Feb 08, 2024 for $*****. 1 investor participated in its latest round. Autolus has 9 institutional investors.
Here is the list of recent funding rounds of Autolus:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Feb 08, 2024 | 6518170 | Post IPO | 8281770 | 9701909 | 8747488 | 3659772 |
Nov 08, 2021 | 6767996 | Post IPO | 1214622 | 7537088 | 4766657 | |
Sep 26, 2017 | 8876478 | Series C | 3295705 | 9099439 |
Access funding benchmarks and valuations. Sign up today!View details of Autolus's funding rounds and investors
Autolus' founders and board of directors
Founder? Claim ProfileThe founders of Autolus is Martin Pule.
Here are the details of Autolus' key team members:
- Martin Pule: Founder of Autolus. Contact Info: 1 email address
Autolus' Board of Directors
Autolus's board has 4 active members. Christian Itin and John Berriman are part of team and Christopher Michael James Williams and Patrick Paul Mcilvenny are independent board members.Here is the list of Autolus' board of directors:
Name | Type | Representing | Status | Duration |
|---|---|---|---|---|
Team | - | Current | 8y 2m | |
hgsptth | Team | - | Current | 8y 4m |
Independent board member | - | Current | 1y 0m | |
fbnxqxq | Independent board member | - | Current | 6y 2m |
hh{fxzg | Independent board member | - | Past | 6y 7m |
View details of Autolus's Founder profiles and Board Members
Autolus' employee count trend
Autolus has 732 employees as of Jul 26. Here is Autolus's employee count trend over the years:
Uncover Autolus' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Autolus's Competitors and alternates
Top competitors of Autolus include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Autolus, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
59th | Autolus 2015, London (United Kingdom), Public | Clinical-stage biopharmaceutical provider developing CAR T therapies for cancer and autoimmune diseases | $181M | 65/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Autolus's competitors? Click here to see the top ones
Autolus's Investments and acquisitions
Autolus has made no investments or acquisitions yet.
Reports related to Autolus
Here is the latest report on Autolus's sector:
News related to Autolus
Filter this listMedia has covered Autolus for a total of 18 events in the last 1 year, 6 of them have been about company updates and 2 about people movement.
•
Autolus outlines $140M-$150M 2026 AUCATZYL revenue, targets 65%-70% gross margin in 12-18 months (NASDAQ:AUTL)Seeking Alpha•Aug 11, 2026•Autolus
•
Autolus Therapeutics GAAP EPS of -$0.15 beats by $0.04, revenue of $45.69M beats by $5.54M (AUTL:NASDAQ)Seeking Alpha•Aug 11, 2026•Autolus
•
Autolus Therapeutics Secures Up to $250 Million Credit Facility with Perceptive AdvisorsGlobeNewswire•Aug 03, 2026•Autolus
•
Autolus Therapeutics Receives Prix Galien UK Award for Best Biotechnology ProductGlobeNewswire•Jun 12, 2026•Autolus
•
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual MeetingGlobeNewswire•May 21, 2026•Autolus
•
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updatesgcs-web.com•May 14, 2026•Autolus
•
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reductiongcs-web.com•Apr 29, 2026•Autolus
•
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updatesgcs-web.com•Mar 27, 2026•Autolus
•
Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM PlatformBusiness Wire•Jan 06, 2026•Autolus, Cellares
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Autolus
Explore our recently published companies
- Christina Homes - United States based, 1983 founded, Unfunded company
- Alvarez & Marsal Property Investments - New York based, 2013 founded, Unfunded company
- AIF Global - New York based, 2005 founded, Unfunded company
- All Phase Contracting - United States based, Unfunded company
- Doc.Series - Switzerland based, 2014 founded, Public company
- ec design and print - Tullahoma based, 2013 founded, Public company
